Fredag 27 December | 13:03:14 Europe / Stockholm
Svenska | English

Lipidor AB

Bifogade filer

Kursutveckling under dagen för detta pressmeddelande (SEK).

Likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-08-28 08:30 Kvartalsrapport 2025-Q2
2025-06-03 N/A Årsstämma
2025-02-28 08:30 Bokslutskommuniké 2024
2024-08-28 - Kvartalsrapport 2024-Q2
2024-06-07 - X-dag ordinarie utdelning LIPI 0.00 SEK
2024-06-05 - Årsstämma
2024-05-21 - Extra Bolagsstämma 2024
2024-02-28 - Bokslutskommuniké 2023
2023-11-22 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-06-09 - X-dag ordinarie utdelning LIPI 0.00 SEK
2023-06-08 - Årsstämma
2023-05-11 - Kvartalsrapport 2023-Q1
2023-02-22 - Bokslutskommuniké 2022
2023-01-17 - Extra Bolagsstämma 2022
2022-11-23 - Kvartalsrapport 2022-Q3
2022-08-24 - Kvartalsrapport 2022-Q2
2022-06-03 - X-dag ordinarie utdelning LIPI 0.00 SEK
2022-06-02 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-23 - Bokslutskommuniké 2021
2021-11-25 - Kvartalsrapport 2021-Q3
2021-08-24 - Kvartalsrapport 2021-Q2
2021-06-09 - X-dag ordinarie utdelning LIPI 0.00 SEK
2021-06-08 - Årsstämma
2021-06-08 - Extra Bolagsstämma 2021
2021-05-06 - Kvartalsrapport 2021-Q1
2021-02-23 - Bokslutskommuniké 2020
2020-11-26 - Kvartalsrapport 2020-Q3
2020-08-27 - Kvartalsrapport 2020-Q2
2020-08-11 - Extra Bolagsstämma 2020
2020-06-12 - X-dag ordinarie utdelning LIPI 0.00 SEK
2020-06-11 - Årsstämma
2020-05-19 - Kvartalsrapport 2020-Q1
2020-02-25 - Bokslutskommuniké 2019
2019-11-21 - Kvartalsrapport 2019-Q3

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Lipidor är verksamt inom läkemedelsbranschen. Bolaget arbetar med forskning och utveckling inom preklinisk samt klinisk fas. Störst affärsverksamhet återfinns inom utveckling av läkemedel som vidare används för behandling av diverse hudsjukdomar. Exempel på sjukdomar som behandlas inkluderar exempelvis psoriasis, olika hudinfektioner samt atopisk dermatit. Huvudkontoret ligger i Solna.
Lipidor announces first patient enrolled in Phase III study of AKP02G2 for topical treatment of psoriasis
2024-09-24 18:30:00

STOCKHOLM, Sweden, 24 September 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the first patient has been enrolled in the Phase III clinical study with AKP02G2.

The drug candidate AKP02G2 combines calcipotriol and betamethasone and is based on Lipidor's patented AKVANO® technology. The goal of AKP02G2 is to offer a patient-friendly and fast-drying spray for the treatment of mild to moderate psoriasis with equivalent effect to the market-leading Enstilar.

The clinical Phase III study is being conducted by Cliantha, the company's contracted CRO (Clinical Research Organisation), which together with Lipidor has carried out solid preparatory work to enable the start of the study according to plan. As of today, the work has resulted in the first of the 294 patients being included in the study.

"It is extremely positive and an important milestone for us to have now recruited the first patient and that the clinics are ready to receive patients. We look forward to presenting the first results from the study in about six months", says Ola Holmlund, CEO of Lipidor.

Lipidor will follow the recruitment closely and keep the market updated.

Publication

The information was provided for publication by Lipidor’s CEO on 24 September 2024 at 6.30pm (CEST).

For more information, please contact:

Ola Holmlund, CEO, Lipidor AB (publ)
Telephone: +46 (0) 72 50 70 369
Email: ola.holmlund@lipidor.se

The company’s Certified Adviser is Carnegie Investment Bank AB (publ).

About Lipidor AB
Lipidor AB (www.lipidor.se) is a pharmaceutical development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The company can develop topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances. Lipidor’s priority project is AKP02G2, which focusses on psoriasis.

About AKVANO®
AKVANO® is an innovative water-free and sprayable technology for formulating medicines and is particularly suitable for local application on, for example, the skin. AKVANO® is made up of carefully selected lipids which, together with a volatile solvent, form the carrier of selected active substances. By combining different lipids, AKVANO® can be optimized to achieve the desired function of active components in the formulation. When applied to the skin, the solvent evaporates and a thin lipid layer is formed on the skin surface for effective release of the active substance.

Attachments
Lipidor announces first patient enrolled in Phase III study of AKP02G2 for topical treatment of psoriasis

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden